Rare Skin Reactions Linked to GLP-1 Drugs: What Clinicians Should Know

Reported cutaneous reactions to GLP-1 agonists include dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions. These are rare but clinically significant. Diagnosis requires clinical suspicion, thorough medication history, and supporting histopathology when available. Management centers on stopping the GLP-1 drug and tailoring anti-inflammatory or immunomodulatory treatment to the specific reaction type.

Narrative review of published case reports and case series documenting cutaneous adverse reactions attributed to GLP-1 agonist use.

Millions of people now take GLP-1 drugs. While skin reactions are rare, clinicians need to recognize them promptly since they can be mistaken for other dermatological conditions. As prescribing expands to weight loss populations, these reactions may become more frequently encountered.

As GLP-1 drugs move from niche diabetes treatment to mass-market weight loss medication, understanding the full spectrum of adverse reactions — including rare skin reactions — becomes increasingly important for patient safety.

Based entirely on case reports and case series — the lowest level of clinical evidence. No incidence rates can be calculated. Publication bias likely overrepresents unusual reactions. Cannot establish causation versus coincidence in individual cases.